Catalyst
Slingshot members are tracking this event:
Corcept's (CORT) first 40 patients enrolled in open-label Phase 3 RELIANT trial of relacorilant + nab-paclitaxel in patients with metastatic pancreatic cancer expected in first half 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CORT | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 22, 2021
Occurred Source:
https://ir.corcept.com/news-releases/news-release-details/preliminary-results-reliant-trial-relacorilant-plus-nab
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Reliant Trial, Relacorilant, Nab-paclitaxel, Metastatic Pancreatic Cancer
